OBJECTIVES: To compare clinical practice guideline (CPG) recommendations and reported physician management of acute paediatric asthma in the 11 largest paediatric emergency departments, all of which have CPGs, in Australia (n = 9) and New Zealand (n = 2). All 11 sites participate in the Paediatric Research in Emergency Departments International Collaborative (PREDICT) research network. METHODS: (a) A review of CPGs for acute childhood asthma from all PREDICT sites. (b) A standardised anonymous survey of senior emergency doctors at PREDICT sites investigating management of acute childhood asthma. RESULTS: CPGs for mild to moderate asthma were similar across sites and based on salbutamol delivery by metered dose inhaler with spacer and oral prednisolone. In severe to critical asthma, differences between sites were common and related to recommendations for: ipratropium use; metered-dose inhaler versus nebulised delivery of salbutamol in severe asthma; use of intravenous aminophylline, intravenous magnesium and dosing of intravenous salbutamol in critical asthma. The questionnaire (78 of 83 doctors responded) also revealed significant differences between doctors in the treatment of moderate to severe asthma. Ipratropium was used for moderate asthma by 42%. For severe to critical asthma, nebulised delivery of salbutamol was preferred by 79% of doctors over metered dose inhalers. For critical asthma, doctors reported using intravenous aminophylline in 45%, intravenous magnesium in 55%, and intravenous salbutamol in 87% of cases. Thirty-nine different dosing regimens for intravenous salbutamol were reported. CONCLUSIONS: CPG recommendations and reported physician practice for mild to moderate paediatric asthma management were broadly similar across PREDICT sites and consistent with national guidelines. Practice was highly variable for severe to critical asthma and probably reflects limitations of available evidence. Areas of controversy, in particular the comparative efficacy of intravenous bronchodilators, would benefit from multi-centre trials. Collaborative development of CPGs should be considered.
OBJECTIVES: To compare clinical practice guideline (CPG) recommendations and reported physician management of acute paediatric asthma in the 11 largest paediatric emergency departments, all of which have CPGs, in Australia (n = 9) and New Zealand (n = 2). All 11 sites participate in the Paediatric Research in Emergency Departments International Collaborative (PREDICT) research network. METHODS: (a) A review of CPGs for acute childhood asthma from all PREDICT sites. (b) A standardised anonymous survey of senior emergency doctors at PREDICT sites investigating management of acute childhood asthma. RESULTS: CPGs for mild to moderate asthma were similar across sites and based on salbutamol delivery by metered dose inhaler with spacer and oral prednisolone. In severe to critical asthma, differences between sites were common and related to recommendations for: ipratropium use; metered-dose inhaler versus nebulised delivery of salbutamol in severe asthma; use of intravenous aminophylline, intravenous magnesium and dosing of intravenous salbutamol in critical asthma. The questionnaire (78 of 83 doctors responded) also revealed significant differences between doctors in the treatment of moderate to severe asthma. Ipratropium was used for moderate asthma by 42%. For severe to critical asthma, nebulised delivery of salbutamol was preferred by 79% of doctors over metered dose inhalers. For critical asthma, doctors reported using intravenous aminophylline in 45%, intravenous magnesium in 55%, and intravenous salbutamol in 87% of cases. Thirty-nine different dosing regimens for intravenous salbutamol were reported. CONCLUSIONS: CPG recommendations and reported physician practice for mild to moderate paediatric asthma management were broadly similar across PREDICT sites and consistent with national guidelines. Practice was highly variable for severe to critical asthma and probably reflects limitations of available evidence. Areas of controversy, in particular the comparative efficacy of intravenous bronchodilators, would benefit from multi-centre trials. Collaborative development of CPGs should be considered.
Authors: Charlotte Koldeweij; Nicholas Appelbaum; Carmen Rodriguez Gonzalvez; Joppe Nijman; Ruud Nijman; Ruchi Sinha; Ian Maconochie; Jonathan Clarke Journal: PLoS One Date: 2022-05-17 Impact factor: 3.752
Authors: Susan L Bratton; Christopher J L Newth; Athena F Zuppa; Frank W Moler; Kathleen L Meert; Robert A Berg; John Berger; David Wessel; Murray Pollack; Rick Harrison; Joseph A Carcillo; Thomas P Shanley; Teresa Liu; Richard Holubkov; J Michael Dean; Carol E Nicholson Journal: Pediatr Crit Care Med Date: 2012-07 Impact factor: 3.624
Authors: Simon Craig; Franz E Babl; Stuart R Dalziel; Charmaine Gray; Colin Powell; Khalid Al Ansari; Mark D Lyttle; Damian Roland; Javier Benito; Roberto Velasco; Julia Hoeffe; Diana Moldovan; Graham Thompson; Suzanne Schuh; Joseph J Zorc; Maria Kwok; Prashant Mahajan; Michael D Johnson; Robert Sapien; Kajal Khanna; Pedro Rino; Javier Prego; Adriana Yock; Ricardo M Fernandes; Indumathy Santhanam; Baljit Cheema; Gene Ong; Shu-Ling Chong; Andis Graudins Journal: Trials Date: 2020-01-13 Impact factor: 2.279
Authors: Simon S Craig; Stuart R Dalziel; Colin Ve Powell; Andis Graudins; Franz E Babl; Carole Lunny Journal: Cochrane Database Syst Rev Date: 2020-08-05
Authors: John Cronin; Una Kennedy; Siobhan McCoy; Sinéad Nic An Fhailí; Gloria Crispino-O'Connell; John Hayden; Abel Wakai; Sean Walsh; Ronan O'Sullivan Journal: Trials Date: 2012-08-21 Impact factor: 2.279
Authors: Shelley A Boeschoten; Ruben S van der Crabben; Annemie L M Boehmer; Matthijs de Hoog; Corinne M P Buysse Journal: Case Rep Pediatr Date: 2019-09-09